seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for ...

Development of quantitative biomarker strategies for proteopathies through seragy’s proprietary SeRAS® technologyExpansion of the company’s laboratory and analytical capabilities with funding from Commerzbank, the Mittelständische Beteiligungsgesellschaft (MBG), and the State of Lower SaxonySeparate funding from The Michael J. Fox Foundation…